Bhavana Kunkalikar

Bhavana Kunkalikar

Bachelor of Pharmacy

Pharmaceutical Sciences, Pathophysiology

Bhavana Kunkalikar is a medical writer based in Goa, India. Her academic background is in Pharmaceutical sciences and she holds a Bachelor's degree in Pharmacy. Her educational background allowed her to foster an interest in anatomical and physiological sciences. Her college project work based on ‘The manifestations and causes of sickle cell anemia’ formed the stepping stone to a life-long fascination with human pathophysiology.

See more

After completing her Bachelor’s degree, she gained considerable industrial experience in the maintenance and upkeep of finished retention samples and testing of water samples from across the manufacturing facility. However, in the wake of the pandemic, her passion for scientific writing urged her to take up more writing projects. She is now a full-time content writer at a digital marketing agency in Bengaluru, India. Her pursuit to expand her horizons led her to medical writing that allowed her to amalgamate her passion for writing with her academic background.  

Her childhood dream of becoming a writer, rooted in the fascination with fairy tales and mystery thrillers, led her to play the part of the College Magazine Secretary and undertake the responsibilities of editor-in-chief. This encouraged her to participate in various college-level story writing competitions and win a handful of them, resulting in some of her first pieces of fictional write-ups.

Outside of work, she is interested in reading and writing fiction, with Stephen King being her go-to writer to read and she aspires to discover and read more writers from the technical field. She also plays the keyboard for pleasure and is admittedly bad at it.

See less

Articles from Bhavana

Monoclonal-antibody combination AZD7442 prevents COVID-19

Monoclonal-antibody combination AZD7442 prevents COVID-19

Antibody escape in SARS-CoV-2 Omicron spike protein

Antibody escape in SARS-CoV-2 Omicron spike protein

Study demonstrates that a low-dose, bivalent, unmodified mRNA vaccine against SARS-CoV-2 is highly efficacious

Study demonstrates that a low-dose, bivalent, unmodified mRNA vaccine against SARS-CoV-2 is highly efficacious

Booster dose of BNT162b2 mRNA vaccine induces a high cross-neutralizing response against SARS-CoV-2 variants

Booster dose of BNT162b2 mRNA vaccine induces a high cross-neutralizing response against SARS-CoV-2 variants

Physical and mental characteristics post-COVID-19 infection

Physical and mental characteristics post-COVID-19 infection

Association between SARS-CoV-2 Omicron viral load and vaccination history

Association between SARS-CoV-2 Omicron viral load and vaccination history

Impact of binding antibody titers and RBD-ACE2 interaction inhibition titers on Omicron breakthrough infections

Impact of binding antibody titers and RBD-ACE2 interaction inhibition titers on Omicron breakthrough infections

Polyethylene glycol-specific antibody responses induced by mRNA-1273 COVID-19 vaccine

Polyethylene glycol-specific antibody responses induced by mRNA-1273 COVID-19 vaccine

Study investigates co-metabolism during SARS-CoV-2 infection

Study investigates co-metabolism during SARS-CoV-2 infection

Exploring the vaccine effectiveness of COVID-19 booster vaccine doses

Exploring the vaccine effectiveness of COVID-19 booster vaccine doses

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.